

PCT

ATTORNEY DOCKET NO.: 056291-5038

#3

CAMERON et al.

Appln. No.: 09/889,409

Filed: July 17, 2001

FOR: USE OF 3-HYDROXY-3-METHYLGLUTARYL
COENZYME A REDUCTASE INHIBITORS FOR
THE MANUFACTURE OF A MEDICAMENT
FOR THE TREATMENT OF DIABETIC
NEUROPATHY

Commissioner of Patents
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT

Attached is a Form PTO-1449 listing the enclosed documents and an International Search Report dated May 29, 2000 citing a number of the enclosed documents. See the degree of relevancy and the particular passages cited for each document in the Search Report.

The present Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits, and therefore no certification under 37 CFR §1.97(e) or fee under 37 CFR §1.17(p) is required.

This Information Disclosure Statement is intended to be in full compliance with the rules, but should the Examiner find any part of its required content to have been omitted, prompt notice to that effect is earnestly solicited, along with additional time under Rule 97(f), to enable Applicant to fully comply.




Should a first Action on the merits have been issued on the same day as or before this IDS is filed, please accept this IDS under Rule 97(c) and charge the requisite fee to our Deposit Account under Order No. 056291/5038 and proceed to consider this IDS.

Consideration of the foregoing and enclosures plus the return of a copy of the herewith filed Form PTO-1449 with the Examiner's initials in the left column per MPEP 609 along with an early action on the merits of this application are earnestly solicited.

Respectfully Submitted,
Morgan Lewis & Bockius LLP

By:



Donald J. Bird
Registration No. 25,323
Tel. No.: (202) 739-5320
Fax No.: (202) 739-3001

Date: February 27, 2002
Morgan Lewis & Bockius LLP
Customer No. **009629**
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
Tel. No.: 202-739-3000
DJB:mk